Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.

Murielle RousselNathalie TexierVirginie NaelJacopo BitettiPrani PakaNaima KerboucheLynda SailXavier ColinXavier Leleu

Published in: European journal of haematology (2024)

ALFA, the largest real-world cohort conducted so far, confirms the results of belantamab mafodotin as reported in the DREAMM-2 clinical trial. The clinical benefit is significant as long as the patient is a responder.

Keyphrases

multiple myeloma
clinical trial
acute lymphoblastic leukemia
replacement therapy
acute myeloid leukemia
case report
hodgkin lymphoma
open label
randomized controlled trial
smoking cessation